TRAILR1/TNFRSF10A Antibody (32A1380) | Novus Biologicals NB100-56747 product information

product summary

company name :

Novus Biologicals

other brands :

IMGENEX

product type :

antibody

product name :

TRAILR1/TNFRSF10A Antibody (32A1380)

catalog :

NB100-56747

quantity :

0.1 mg (also 0.025 mg)

price :

329 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

32A1380

reactivity :

human

application :

western blot, immunocytochemistry, flow cytometry

more info or order :

Novus Biologicals product webpage

citations: 41

Published Application/Species/Sample/Dilution	Reference
western blot; human	Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J, et al. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci Rep. 2013;3:3565 pubmed publisher
western blot; human	Park S, Cho D, Andera L, Suh N, Kim I. Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. Mol Cell Biochem. 2013;383:39-48 pubmed publisher
flow cytometry; human	Le Poole I, ElMasri W, Denman C, Kroll T, Bommiasamy H, Lyons Eiben G, et al. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother. 2008;57:789-97 pubmed
	Chen L, Hao M, Yan J, Sun L, Tai G, Cheng H, et al. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation. J Biol Chem. 2021;296:100515 pubmed publisher
	Yu J, Berga S, Zou W, Rajakumar A, Man M, Sidell N, et al. Human Endometrial Stromal Cell Differentiation is Stimulated by PPARβ/δ Activation: New Targets for Infertility?. J Clin Endocrinol Metab. 2020;105: pubmed publisher
	Scimeca M, Anemona L, Granaglia A, Bonfiglio R, Urbano N, Toschi N, et al. Plaque calcification is driven by different mechanisms of mineralization associated with specific cardiovascular risk factors. Nutr Metab Cardiovasc Dis. 2019;29:1330-1336 pubmed publisher
	Alyessary A, Yap A, Othman S, Rahman M, Al Namnam N, Radzi Z. Is there an optimal initial amount of activation for midpalatal suture expansion? : A histomorphometric and immunohistochemical study in a rabbit model. J Orofac Orthop. 2018;79:169-179 pubmed publisher
	Jayash S, Hashim N, Misran M, Baharuddin N. Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model. Peerj. 2017;5:e3513 pubmed publisher
	Xue M, Ge Y, Yu C, Zheng Z, He X, Zhao J. Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Mol Med Rep. 2017;16:978-982 pubmed publisher
	Wada S, Kanzaki H, Narimiya T, Nakamura Y. Novel device for application of continuous mechanical tensile strain to mammalian cells. Biol Open. 2017;6:518-524 pubmed publisher
	Wu Y, Su W, Wu P, Shen P, Jou I. Degradation of elastic fiber and elevated elastase expression in long head of biceps tendinopathy. J Orthop Res. 2017;35:1919-1926 pubmed publisher
	Jayash S, Hashim N, Misran M, Baharuddin N. In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications. Peerj. 2016;4:e2229 pubmed publisher
	Cheng M, Wahafu T, Jiang G, Liu W, Qiao Y, Peng X, et al. A novel open-porous magnesium scaffold with controllable microstructures and properties for bone regeneration. Sci Rep. 2016;6:24134 pubmed publisher
	Foster K, Jane E, Premkumar D, Morales A, Pollack I. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int J Oncol. 2015;47:506-16 pubmed publisher
	Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone M, et al. Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 2016;19:412-420 pubmed publisher
	Magro C, Momtahen S, Hagen J. Osteopontin expression in biopsies of calciphylaxis. Eur J Dermatol. 2015;25:20-5 pubmed publisher
	Nguyen T, Min Y, Lee B. Nanoparticle biphasic calcium phosphate loading on gelatin-pectin scaffold for improved bone regeneration. Tissue Eng Part A. 2015;21:1376-87 pubmed publisher
	Fujita K, Fukuda M, Fukui H, Horie M, Endoh S, Uchida K, et al. Intratracheal instillation of single-wall carbon nanotubes in the rat lung induces time-dependent changes in gene expression. Nanotoxicology. 2015;9:290-301 pubmed publisher
	Goswami R, Millo T, Mishra S, Das M, Kapoor M, Tomar N, et al. Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for Basal Ganglia calcification in hypoparathyroidism. J Clin Endocrinol Metab. 2014;99:1741-8 pubmed publisher
	Nguyen T, Lee B. A combination of biphasic calcium phosphate scaffold with hyaluronic acid-gelatin hydrogel as a new tool for bone regeneration. Tissue Eng Part A. 2014;20:1993-2004 pubmed publisher
	Nikodemova M, Small A, Smith S, Mitchell G, Watters J. Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galectin-3 and osteopontin, and blunted inflammatory responses in ALS rats. Neurobiol Dis. 2014;69:43-53 pubmed publisher
	Abdulghani J, Allen J, Dicker D, Liu Y, Goldenberg D, Smith C, et al. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS ONE. 2013;8:e75414 pubmed publisher
	Bondarenko A, Angrisani N, Meyer Lindenberg A, Seitz J, Waizy H, Reifenrath J. Magnesium-based bone implants: immunohistochemical analysis of peri-implant osteogenesis by evaluation of osteopontin and osteocalcin expression. J Biomed Mater Res A. 2014;102:1449-57 pubmed publisher
	Allen J, Ferrini R, Dicker D, Batzer G, Chen E, Oltean D, et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther. 2012;11:2087-95 pubmed publisher
	Xu L, Song C, Ni M, Meng F, Xie H, Li G. Cellular retinol-binding protein 1 (CRBP-1) regulates osteogenenesis and adipogenesis of mesenchymal stem cells through inhibiting RXR?-induced ?-catenin degradation. Int J Biochem Cell Biol. 2012;44:612-9 pubmed publisher
	Rui Y, Lui P, Rolf C, Wong Y, Lee Y, Chan K. Expression of chondro-osteogenic BMPs in clinical samples of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2012;20:1409-17 pubmed publisher
	Jane E, Premkumar D, Pollack I. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther. 2011;10:198-208 pubmed publisher
	Lin Y, Chen S, Yue P, Zou W, Benbrook D, Liu S, et al. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008;68:5335-44 pubmed publisher
	Tsurushima H, Yuan X, Dillehay L, Leong K. Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors. Cancer Gene Ther. 2007;14:706-16 pubmed
	Lee S, Kim Y, Kim C, Seol S, Kim J, Cho S, et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol. 2005;175:8226-35 pubmed
	Kroll T, Bommiasamy H, Boissy R, Hernandez C, Nickoloff B, Mestril R, et al. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol. 2005;124:798-806 pubmed
	Ren Y, Wagner K, Knee D, Aza Blanc P, Nasoff M, Deveraux Q. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell. 2004;15:5064-74 pubmed
	Liu X, Yue P, Khuri F, Sun S. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004;64:5078-83 pubmed
	Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. 2003;22:1653-62 pubmed
	Chen X, Kandasamy K, Srivastava R. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 2003;63:1059-66 pubmed
	Guan B, Yue P, Lotan R, Sun S. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene. 2002;21:3121-9 pubmed
	Bretz J, Mezosi E, Giordano T, Gauger P, Thompson N, Baker J. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ. 2002;9:274-86 pubmed
	Lu G, Janjic B, Janjic J, Whiteside T, Storkus W, Vujanovic N. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol. 2002;168:1831-9 pubmed
	Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, et al. Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem. 2002;84:420-32 pubmed
	Krishnamoorthy B, Darnay B, Aggarwal B, Dinh D, Kouraklis G, Olivero W, et al. Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2001;7:4195-201 pubmed
	Sridhar S, Ali A, Liang Y, El Etreby M, Lewis R, Kumar M. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res. 2001;61:7179-83 pubmed

product information

brand :

Novus

master code :

NB100-56747

SKU :

NB100-56747

product name :

TRAILR1/TNFRSF10A Antibody (32A1380)

description :

The TRAILR1/TNFRSF10A Antibody (32A1380) from NB100-56747 is a nb100-56747 antibody to . This antibody reacts with apoptosis, cancer. The TRAILR1/TNFRSF10A Antibody (32A1380) has been validated for the following applications: O00220.

target :

TRAILR1/TNFRSF10A

category :

Primary Antibodies

unit sizes :

0.1 mg (also 0.025 mg)

buffer :

PBS

clonality :

Monoclonal

clone :

32A1380

concentration :

0.5 mg/ml

conjugate :

Unconjugated

host :

Mouse

immunogen :

This monoclonal antibody was raised against a peptide corresponding to amino acid 2 to 21 of human DR4.

isotype :

IgG1 Kappa

purity :

Protein G purified

species :

Human

gene symbol :

TNFRSF10A

accessionNumbers :

O00220

applications :

Western Blot, Simple Western, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Flow (Cell Surface), Flow (Intracellular), CyTOF-ready

USD :

329 USD

alt names :

APO2, CD261, CD261 antigen, cytotoxic TRAIL receptor, Death receptor 4, DR4, DR4 TRAIL receptor 1, TNF-related apoptosis inducing ligand receptor 1, TNF-related apoptosis-inducing ligand receptor 1, TRAIL-R1, TRAILR-1, TRAILR1MGC9365, tumor necrosis factor receptor superfamily member 10A, tumor necrosis factor receptor superfamily, member 10a

storage :

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

more info or order :

Novus Biologicals product webpage